Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial
Authors:
- C. ZadikoffCZC. Zadikoff
- P.M. WadiaPWP.M. Wadia
- J. MiyasakiJ. Miyasaki
- R. ChenRCR. Chen
- A.E. LangALA.E. Lang
- J. SoJSJ. So
- S.H. FoxSFS.H. Fox
- 1 July 2011
- journal article
- Published by Elsevier in Basal Ganglia
- Vol. 1 (2) , 91-95
Abstract
No abstract availableKeywords
Funding Information
- Parkinson Society Canada
- Michael J. Fox Foundation for Parkinson's Research
- Dystonia Medical Research Foundation
- National Institutes of Health
- Canadian Institutes of Health Research
This publication has 30 references indexed in Scilit:
- 5‐HT1Areceptors are involved in the cannabidiol‐induced attenuation of behavioural and cardiovascular responses to acute restraint stress in ratsBritish Journal of Pharmacology, 2008
- Subcellular localization of type 1 cannabinoid receptors in the rat basal gangliaNeuroscience, 2006
- Emerging properties of cannabinoid medicines in management of multiple sclerosisTrends in Neurosciences, 2005
- Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled studyMovement Disorders, 2005
- Δ9‐tetrahydrocannabinol improves motor control in a patient with musician's dystoniaMovement Disorders, 2004
- Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's diseaseMovement Disorders, 2002
- Globus pallidus internus pallidotomy for generalized dystoniaMovement Disorders, 1997
- A 2-DEOXYGLUCOSE STUDY OF THE EFFECTS OF DOPAMINE AGONISTS ON THE PARKINSONIAN PRIMATE BRAINBrain, 1992
- Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxideNeuropharmacology, 1988
- Open label evaluation of cannabidiol in dystonic movement disordersInternational Journal of Neuroscience, 1986